Aridis Pharmaceuticals, Inc, a United States-based biopharmaceutical company, has reported its financial results for the second quarter of fiscal 2020, it was reported on Tuesday.
The company reported an increase in grant revenue to USD1m for second quarter ended 30 June 2020 from zero for the quarter ended 30 June 2019.
The firm posted net loss for the quarter ended 30 June 2019 at around USD4.2m or USD0.47 loss per share, compared to a net loss of around USD8.4m or USD1.03 net loss per share for the year-ago period.
'The second quarter proved to be a strong period of progress as we continue on our mission to become the leader in developing novel anti-infective treatments for lung infections,' commented Vu Truong, PhD, Aridis Pharmaceuticals' chief executive officer.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients